MEN2312 not checked

Stemline Therapeutics, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
2 active
2 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Hematological Malignancy, Advanced Breast Cancer
Main trialPhase 1/2
“This study will evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and activity of MEN2312 in participants with hematological malignancies.”In the company’s words, NCT07873827 on ClinicalTrials.gov

Other drugs for Hematological Malignancy

All 106 drugs for Hematological Malignancy

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1/2Not yet recruiting 12 May 2028 KATALYST-HEME-01: Study of the KAT6 Inhibitor MEN2312 in Heme Malignancies
Phase 1Recruiting 24 Oct 2027 A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MEN2312

Following is part of Solo: you see every change to MEN2312 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in